SIRT1 and osteoporosis: The current demonstration of the in vivo efficacy of the SIRT1 agonist SRT1720 on bone mass adds weight to the idea that this Sirtuin is a strong pharmacological target for treating both age-related and post-menopausal osteoporosis.